[Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke].
To assess the efficacy of the cytoprotective neuropeptide cortexin in the complex treatment in acute and early rehabilitation stages of ischemic stroke (II). A multicenter prospective double-blind placebo-controlled trial has been carried out. Two hundreds and seventy-two patients with II have been enrolled in the trial. Cortexin was administered in low doses (10 mg three times a day intramuscular, using the following schemes: group 1: 2 courses of cortexin; group 2: 1 course of cortexin with the following course of placebo; group 3: two courses of placebo. The duration of treatment was 70 days. Patients were examined during 4 visits using clinical tests and instrumental methods. High efficacy and safety of cortexin in the complex treatment of patients with II has been shown. The best therapeutic effect was seen in group 1 (two 10-day courses of cortexin). The results were confirmed by the pharmacoeconomic analysis of treatment tactics based on the estimation of "net monetary benefit". Cortexin is recommended for treatment and rehabilitation of patients with II.